Archives

U.S. Ambassador to Israel Mike Huckabee to Deliver Yeshiva University’s 2026 Commencement Address and Receive Presidential Medallion for Global Leadership

B As America marks its 250th anniversary, Yeshiva University celebrates shared values, enduring U.S.-Israel ties and the next generation of leaders. NEW YORK and JERUSALEM,… Login to continue reading Login…

Read MoreU.S. Ambassador to Israel Mike Huckabee to Deliver Yeshiva University’s 2026 Commencement Address and Receive Presidential Medallion for Global Leadership

Stealth BioTherapeutics Provides Commercial Launch Update and Pipeline Progress Across Mitochondrial Disease Portfolio

B – FORZINITY™ (elamipretide) injection early commercial momentum demonstrates strong patient uptake and rapid access timelines – – Advancing differentiated mitochondrial-targeted pipeline across rare and… Login to continue reading Login…

Read MoreStealth BioTherapeutics Provides Commercial Launch Update and Pipeline Progress Across Mitochondrial Disease Portfolio

Are You All In? Target ALS Goes “All In For ALS Awareness” with Campaign to Highlight the Community and Research Building a World Where Everyone Lives

B NEW YORK, April 30, 2026 /PRNewswire/ — For ALS Awareness Month this May, Target ALS is going “all in”: for research, for community, and… Login to continue reading Login…

Read MoreAre You All In? Target ALS Goes “All In For ALS Awareness” with Campaign to Highlight the Community and Research Building a World Where Everyone Lives

Bambusa Therapeutics Completes Patient Enrollment in the Phase 1b/2a Trial Evaluating BBT001 as a Treatment for Atopic Dermatitis

B – Bambusa’s lead product candidate, BBT001 is a next-generation long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-31 for the… Login to continue reading Login…

Read MoreBambusa Therapeutics Completes Patient Enrollment in the Phase 1b/2a Trial Evaluating BBT001 as a Treatment for Atopic Dermatitis